Evidence based cancer medicine and cost effectiveness

The increasing new treatment possibilities, mainly in medical oncology, escalate the need for evidence based treatments. New anticancer agents are registered with limited information on their positive and negative treatment effects.

Therefore research in evidence based clinical effects takes place after registration. At the same time patients ask for, and physicians often offer treatment with new anticancer agents outside clinical protocols. The effects may include extreme costs for health care systems and unnecessary side effects for patients not responding to the therapies.

If effects are positive, the remission duration is short and the cure rate is low. The key issue is how to develop up-to-date guidelines for evidence based cancer medicine and cost-effectiveness when the treatment possibilities are rapidly changing with a large number of new anticancer agents available on the market? Strategies are at present lacking and the expertise within the EACS can be used to outline a strategy for this important problem.

Lead author: Bengt Jönsson
Co-authors: Frans Rutten, Carin Uyl, Thomas Tursz, Nils Wilking, Jaap Verweij, Ken Paterson

Sorry. You need to upgrade your browser

You are using Internet Explorer 8

This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.

Thank you.